and fused silica. Pharmaceutically acceptable excipients also include flavorants, as well as various additives such as other vitamins and minerals, all solvents, dispersion media, coatings, isotonic and absorption delaying agents, sweeteners and the like, non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, and inert ingredients such as talc and magnesium stearate which are standard excipients in the manufacture of tablets, capsules and other dosage forms.

As used herein the terms "subject" or "patient" are well-recognized in the art, and, are used interchangeably herein to refer to a mammal, including dog, cat, rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, most preferably, a human. In some embodiments, the subject is a subject in need of treatment or a subject with a disease or disorder. However, in other embodiments, the subject can be a normal subject. The term does not denote a particular sex. Thus, adult subjects, whether male or female, are intended to be covered.

The term "an effective amount" refers to an amount necessary to obtain a physiological effect. The physiological effect may be achieved by one application dose or by repeated applications. The dosage administered may, of course, vary depending upon known factors, such as the physiological characteristics of the particular composition; the age, health and weight of the subject; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired and can be adjusted by a person skilled in the art.

As used herein, the terms "prevention" and "preventing," when referring to a disorder or symptom, refers to a reduction in the risk or likelihood that a mammalian subject will develop said disorder, symptom, condition, or indicator after treatment according to the invention, or a reduction in the risk or likelihood that a mammalian subject will exhibit a recurrence of said disorder, symptom, condition, or indicator once a subject has been treated according to the invention and cured or restored to a normal state.

As used herein, the terms "treatment" or "treating," when referring to sexual dysfunction, sexual fitness or wellness, sexual enhancement in both sexes, refers to

CLAIMS

1. A use of a composition consisting of ellagitannins extracts originating from plant extracts of the Fagaceae family having more than 50% by dry weight of ellagitannins or having ellagitannins at a concentration of at least 10% of the total weight of said composition, in the manufacture of a medicament for treating or preventing sexual dysfunctionin both sexes.

2. The use according to claim 1, wherein said ellagitannins extracts originated from plant extracts of the Fagacaea family comprise Roburins or derivatives thereof.

3. The use of claims 1 or 2, wherein the plant extracts of the Fagacaea family are selected among genera *Quercus*, *Castanea*, and *Fagus* or mixtures thereof.

4. The use of claim 3, wherein the plant extracts of the Fagacaea family consists of oak woods extracts.

5. The use of claim 4, wherein the plant extracts of the Fagacaea family consists of *Quercus robur* extracts.

6. The use according to any one of claims 1 to 5, in the form of a food preparation, a dietary supplement, a nutraceutical, or a beverage.

7. The use of anyone of claims 1 to 6, wherein the composition is adapted for an oral administration.

8. A non-therapeutic method for improving sexual fitness of both sexes comprising administering to a subject an effective amount of a composition consisting of ellagitannins extracts having more than 50% by dry weight of ellagitannins or having ellagitannins at a concentration of at least 10% of the total weight of said composition, the ellagitannins extracts originating from plant extracts of the Fagacaea family comprising Roburins or derivatives thereof.

9. The use according to any one of claims 1 to 7, wherein treating or preventing sexual dysfunction comprises increasing male and female libido or sex drive.

10. The use according to any one of claims 1 to 7 wherein treating or preventing sexual dysfunction comprises improving the health of the sexual vascular system linked to blood flow of both sexes.

11. A non-therapeutic method to preserve and maintain sexual responsiveness, endurance and enjoyment in both sexes, administering to a subject a composition consisting of ellagitannins extracts having more than 50% by dry weight of ellagitannins or having ellagitannins at a concentration of at least 10% of the total weight of said composition, the ellagitannins extracts originating from plant extracts of the Fagaceae family.